Results 41 to 50 of about 29,707 (225)

Current Understanding of the Pathogenesis of ANCA-Associated Vasculitis and Novel Treatment Options Targeting Complement Activation

Life
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (ANCA-vasculitis) is an autoimmune disease characterized by inflammation and necrosis of small or medium vessels.
Konstantinos Drouzas, Petros Kalogeropoulos, George Liapis, Sophia Lionaki   +3 more
doaj   +1 more source

Optimal management of Cogan’s syndrome: a multidisciplinary approach [PDF]

, 2017
Cogan's syndrome (CS) is a rare disorder characterized by nonsyphilitic interstitial keratitis (IK) and audio-vestibular symptoms. CS affects mainly young Caucasian adults, mostly during their first three decades of age, and may develop into typical and ...
D'Aguanno, Vittorio, de Vincentiis, Marco, Greco, Antonio, Ralli, Massimo   +3 more
core   +1 more source

Establishment of a mouse model of propylthiouracil‐induced antineutrophil cytoplasmic antibody‐associated vasculitis

Animal Models and Experimental Medicine, EarlyView.
This graphical abstract summarizes our study in which we established a novel murine model of antineutrophil cytoplasmic antibody (ANCA)‐associated vasculitis. Neutrophil recruitment was induced using thioglycolate, followed by timed administration of propylthiouracil and phorbol 12‐myristate 13‐acetate to generate DNase I‐resistant neutrophil ...
Sakiko Masuda, Momo Uchizawa, Chihiro Terasaka, Takumi Abe, Tetsuro Nakamura, Yuka Nishibata, Yusho Ueda, Daigo Nakazawa, Utano Tomaru, Akihiro Ishizu   +9 more
wiley   +1 more source

ANCA-negative pauci-immune renal vasculitis: histology and outcome [PDF]

, 2017
Background. Pauci-immune renal vasculitis with focal glomerular necrosis and crescent formation is usually associated with anti-neutrophil cytoplasmic antibodies (ANCAs).
Beaufils, Hélène, Eisenberger, Ute, Fakhouri, Fadi, Guillevin, Loic, Lesavre, Philippe, Mahr, Alfred, Noël, Laure-Hélène, Vanhille, Philippe   +7 more
core  

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

The Pathogenicity of BPI-ANCA in a Patient With Systemic Vasculitis

Frontiers in Immunology, 2019
Objective: ANCA associated vasculitis (AAV) is characterized by systemic necrotizing vasculitis with the presence of ANCA. Although BPI-ANCA is one of the atypical ANCAs and is occasionally seen in patients with vasculitis, the pathogenicity of BPI-ANCA ...
Sayo Takeda, Kanako Watanabe-Kusunoki, Daigo Nakazawa, Yoshihiro Kusunoki, Saori Nishio, Tatsuya Atsumi   +5 more
doaj   +1 more source

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab

Arthritis &Rheumatology, EarlyView.
Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial.
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators, Reem Al‐jayyousi, Yoshihiro Arimura, Jacqueline Andrews, Simon Bond, Marianna Nodale, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Michael Clarkson, Janak de Zoysa, Vimal Derebail, Tim Doulton, Tomomi Endo, Eri Muso, Tatsuo Tsukamoto, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz‐Singer, Yoshitomo Hamano, Lorraine Harper, Toshiko Ito‐Ihara, Rachel B. Jones, Nader Khalidi, Rainer Klocke, Curry L. Koening, Yoshinori Komagata, Hajime Kono, Shunya Uchida, Carol A. Langford, Peter Lanyon, Sarah Lawman, Raashid Luqmani, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Ken‐ei Sada, Richard Smith, Richard Watts, Robert Spiera, Antoine G. Sreih, Kazuo Suzuki, Vladamir Tesar, Augusto Vaglio, Giles Walters, Caroline Wroe   +62 more
wiley   +1 more source

A case of COVID‐19‐associated C‐ANCA vasculitis, was successfully treated with rituximab therapy

Clinical Case Reports
Key Clinical Message Both C‐anti‐neutrophil cytoplasmic antibody (ANCA) and P‐ANCA vasculitis were reported to be associated with COVID‐19 infection. The ideal management of COVID‐19‐associated ANCA vasculitis is unclear, as the experiences were limited ...
Michael Filoramo, Renish Contractor, Deepak Chandramohan, Prabhat Singh, Nihar Jena, Prathap Kumar Simhadri   +5 more
doaj   +1 more source

Updates in ANCA-associated vasculitis

European Journal of Rheumatology, 2022
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are small-vessel vasculitides that include granulomatosis with polyangiitis (formerly Wegener’s granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (Churg - Strauss syndrome). Renal-limited AAV can be considered a fourth entity. Despite their
Carolyn Ross, Jean-Paul Makhzoum, Christian Pagnoux   +2 more
openaire   +3 more sources

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Arthritis &Rheumatology, EarlyView.
Objective Ear, nose, and throat (ENT) manifestations are common in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There is an unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)–AAV. In a zebrafish model, niclosamide inhibits PR3‐induced granuloma formation.
Benjamin Lim, Wendi Qian, Francis Dowling, Alan Salama, Rona M Smith   +4 more
wiley   +1 more source